A Study Evaluating Financial Toxicity Amongst Hematologic Malignancy Patients in the Bronx
Introduction Financial toxicity (FT) in cancer care is a growing public health problem faced by patients, caregivers, and oncologists . This burden is more pronounced in hematologic malignancies (HM), given the intense nature and novel but costly therapies in this patient population.Underserved comm...
Gespeichert in:
Veröffentlicht in: | Blood 2023-11, Vol.142 (Supplement 1), p.7397-7397 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Introduction
Financial toxicity (FT) in cancer care is a growing public health problem faced by patients, caregivers, and oncologists . This burden is more pronounced in hematologic malignancies (HM), given the intense nature and novel but costly therapies in this patient population.Underserved communities face disproportionately higher financial toxicity of cancer treatment. This study aims to determine the impact of sociodemographic factors and clinical characteristics on the severity of FT in patients treated for HM, largely from underserved communities in a tertiary care hospital in the Bronx.
Methods
This prospective ongoing survey-based study is being carried out at the Montefiore Medical Center, Bronx, NY. All patients were adults categorized into newly diagnosed (ND) patients with HM and those receiving cellular therapy (CT): autologous/allogeneic stem cell transplantation and CAR-T cell therapy. Investigator designed questionnaire was used to obtain sociodemographic and clinical characteristics of the patients, while The Comprehensive Score for Financial Toxicity (COST-FACIT) questionnaire, a validated FT tool, was used to determine the severity of FT for each patient. Patients were given a score based on their answers for the COST-FACIT questionnaire: score 0 = Grade 3 - severe FT; 1-13 = Grade 2 - moderate FT; 14-26 = Grade 1 - mild FT and >26 = Grade 0 - no toxicity. Surveys were administered on day 0, day 30, and day 90. We looked at mean FT scores according to sociodemographic factors, disease type, and treatment arms. The student's t-test ANOVA was used for statistical analysis using SPSS software. This study was approved by the institutional IRB.
Results
We have recruited a total of 72 patients at the time of analysis to date (Table). At Day 0, there were 41 patients in the ND group and 31 patients in the CT group. In the ND group, 31 and 25 of them had completed the day 30 and day 90 survey respectively, while in the CT group, 20 and 9 patients completed the day 30 and day 90 survey, respectively. Seven patients (4 in ND, and 3 in CT cohort) died at the time of their first survey. The mean FT for various demographic and clinical characteristics is summarized in the table. We obtained further information using our questionnaire and correlated it to the COST-FACIT score. On day 0, 10 patients (24.4%) in the ND cohort and 5patients (16%) in the CT cohort reported having difficulty paying for food, shelter, and clothing often to most of the ti |
---|---|
ISSN: | 0006-4971 1528-0020 |
DOI: | 10.1182/blood-2023-188024 |